Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.42 | N/A | +2.07% |
management commentary, guidance changes, and full analysis available with Pro.
| +2.07% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS performance, highlighting their commitment to shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS results this quarter.
Our focus remains on delivering value to our shareholders.
Amgen's earnings report shows a positive surprise in EPS, which contributed to a slight increase in the stock price. The lack of revenue data and future guidance may leave investors cautious. The small stock movement suggests that while the EPS beat is a positive sign, investors are awaiting more comprehensive information on revenue and future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REINSURANCE GROUP AM
Jan 28, 2019